Find Nalmefene Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 58895-64-0, Nalmefene hcl, Revex, Nalmefenehydrochloride, Jf-1 hydrochloride, K7k69qc05x
Molecular Formula
C21H26ClNO3
Molecular Weight
375.9  g/mol
InChI Key
GYWMRGWFQPSQLK-OPHZJPRHSA-N
FDA UNII
K7K69QC05X

Nalmefene Hydrochloride
Nalmefene Hydrochloride is the hydrochloride salt form of nalmefene, a naltrexone analogue with opioid antagonistic property. Nalmefene antagonizes the effects of opioids by competing for the opioid receptors in the CNS. This results in reversal of the effects of the opioids, including reversal of analgesia, euphoria, respiratory depression, hypotension, sedation and physical dependence.
1 2D Structure

Nalmefene Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydrochloride
2.1.2 InChI
InChI=1S/C21H25NO3.ClH/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13;/h4-5,13,16,19,23-24H,1-3,6-11H2;1H/t16-,19+,20+,21-;/m1./s1
2.1.3 InChI Key
GYWMRGWFQPSQLK-OPHZJPRHSA-N
2.1.4 Canonical SMILES
C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O.Cl
2.1.5 Isomeric SMILES
C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O.Cl
2.2 Other Identifiers
2.2.1 UNII
K7K69QC05X
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 6-desoxy-6-methylenenaltrexone

2. Nalmefene

3. Revex

4. Selincro

2.3.2 Depositor-Supplied Synonyms

1. 58895-64-0

2. Nalmefene Hcl

3. Revex

4. Nalmefenehydrochloride

5. Jf-1 Hydrochloride

6. K7k69qc05x

7. (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydrochloride

8. Unii-k7k69qc05x

9. Revex (tn)

10. 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, , Hydrochloride

11. Schembl628721

12. Chembl1201152

13. Dtxsid70891705

14. Bcp08346

15. Nalmefene Hydrochloride [mi]

16. Mfcd27937056

17. Akos016340557

18. Ccg-221179

19. Hs-0037

20. Nalmefene Hydrochloride [mart.]

21. Nalmefene Hydrochloride [vandf]

22. Nalmefene Hydrochloride [who-dd]

23. Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, Hydrochloride, (5alpha)-

24. B7584

25. Nalmefene Hydrochloride [orange Book]

26. D02104

27. Sr-01000000007

28. Sr-01000000007-2

29. Q27282058

30. 17-cyclopropylmethyl-4,5a-epoxy-6-methylenemorphinan-3,14-diol

31. (5?)-17-(cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol Hydrochloride

32. 17-cyclopropylmethyl-4,5a-epoxy-6-methylenemorphinan-3,14-diol Hydrochloride

33. (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol,hydrochloride

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 375.9 g/mol
Molecular Formula C21H26ClNO3
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count4
Rotatable Bond Count2
Exact Mass375.1601214 g/mol
Monoisotopic Mass375.1601214 g/mol
Topological Polar Surface Area52.9 Ų
Heavy Atom Count26
Formal Charge0
Complexity618
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Narcotic Antagonists

Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)


4.2 FDA Pharmacological Classification
4.2.1 Pharmacological Classes
Opioid Antagonists [MoA]; Opioid Antagonist [EPC]

API SUPPLIERS

read-more
read-more

01

Sanofi

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Sanofi Company Banner

02

Rusan Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WCInactive-api NDC KDMF VMF Others AUDIT
Rusan Pharma

03

Purisys LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
German Wound Congress
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Noramco

04

Mallinckrodt Pharmaceuticals

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

German Wound Congress
Not Confirmed
arrow

Mallinckrodt Pharmaceuticals

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
German Wound Congress
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

05

Mallinckrodt Pharmaceuticals

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

German Wound Congress
Not Confirmed
arrow

Mallinckrodt Pharmaceuticals

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
German Wound Congress
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

Sichuan Qingmu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

German Wound Congress
Not Confirmed
arrow

Sichuan Qingmu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
German Wound Congress
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

07

Merck & Co

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

German Wound Congress
Not Confirmed
arrow

Merck & Co

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
German Wound Congress
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Tasmanian Alkaloids Pty Ltd

Australia

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

German Wound Congress
Not Confirmed
arrow

Tasmanian Alkaloids Pty Ltd

Australia

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
German Wound Congress
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Saneca Pharmaceuticals

Slovakia

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

German Wound Congress
Not Confirmed
arrow

10

Guangzhou Tosun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

German Wound Congress
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Sanofi Sa

France
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Flag France
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 5484

Submission : 1984-08-01

Status : Inactive

Type : II

Sanofi Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 34367

Submission : 2019-12-13

Status : Active

Type : II

Rusan Pharma

03

Specgx Llc

Ireland

USDMF

arrow
German Wound Congress
Not Confirmed

03

Specgx Llc

Ireland
arrow
German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35829

Submission : 2021-11-10

Status : Active

Type : II

blank

04

Specgx Llc

Ireland

USDMF

arrow
German Wound Congress
Not Confirmed

04

Specgx Llc

Ireland
arrow
German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-08-25

Pay. Date : 2019-08-22

DMF Number : 15663

Submission : 2001-10-10

Status : Active

Type : II

blank

05

Nv Organon

U.S.A

USDMF

arrow
German Wound Congress
Not Confirmed

05

Nv Organon

U.S.A
arrow
German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 5642

Submission : 1984-12-17

Status : Inactive

Type : II

blank

06

German Wound Congress
Not Confirmed

06

German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-06-23

Pay. Date : 2022-04-01

DMF Number : 36751

Submission : 2022-03-21

Status : Active

Type : II

blank

07

German Wound Congress
Not Confirmed

07

German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 8507

Submission : 1990-03-30

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Rusan Pharma

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

Flag India
Digital Content Digital Content

Nalmefene Hydrochloride

About the Company : Rusan Pharma is a fully integrated global pharmaceutical company specializing in the treatment of addiction & pain management. We manufacture & market a wide range of APIs & formul...

Rusan Pharma is a fully integrated global pharmaceutical company specializing in the treatment of addiction & pain management. We manufacture & market a wide range of APIs & formulations, in the area of controlled substances. Our facilities are GMP-approved by Health Canada, EU, TGA, ANVISA, PIC/S, WHO, Russia & SAHPRA. We have CEP approval for various APIs such as Buprenorphine, Fentanyl, Naltrexone, Methadone, Bisoprolol & we also manufacture Naloxone, Nalbuphine, Nalmefene, Apomorphine, Efflornithine & Sodium Oxybate. We also develop & manufacture various transdermal patches & long-acting formulations such as depot injections & Implants.
Rusan Pharma

02

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefene

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Excipients, Herbal extracts, Formulation of Chinese & Western Medicine. With abundant economic strength, the group has successfully developed to a pharmaceutical group enterprise wich intergrets operation of medicine & related products, processing & manufacturing, and importation & exportation together.
blank

03

OmnisMed Pharmaceuticals

United Kingdom
German Wound Congress
Not Confirmed
arrow

OmnisMed Pharmaceuticals

United Kingdom
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

About the Company : OmnisMed Pharmaceuticals believes that good healthcare must be accessible to everyone; That is the core of our philosophy. We are experts in providing a wide range of high-quality ...

OmnisMed Pharmaceuticals believes that good healthcare must be accessible to everyone; That is the core of our philosophy. We are experts in providing a wide range of high-quality pharmaceutical products, highly tested and approved controlled drugs, and fully certifiable medical devices. All our suppliers hold several GMPs and certifications which are readily accepted by developed and developing markets. The high daily manufacturing capacity of our facilities and our distribution network allows us to quickly fulfill large orders and ensure our manufacturing process is cost-effective.
blank

04

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

About the Company : We are the largest pharmaceutical company in Slovakia with site originally established in the 1940s. Our multi-purpose headquarters is easily reachable from all central European hu...

We are the largest pharmaceutical company in Slovakia with site originally established in the 1940s. Our multi-purpose headquarters is easily reachable from all central European hubs like Vienna, Prague and Budapest. We, at Saneca, carry on the tradition of commitments to quality and customer service level. Everything that we do we approach from the customer perspective.
blank

05

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

About the Company : Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enterprise in China. Focused on generic drugs while venturing into innovative on...

Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enterprise in China. Focused on generic drugs while venturing into innovative ones, the group is dedicated to offering comprehensive solutions to the industry. Presently, Hankang has crafted over 200 varieties for 600+ domestic and international companies, serving 10+ innovative drugs. It has successfully developed more than 10 initial generic drugs, with over 20 varieties endorsed by the top three domestic companies and 30 exceeding a 100 million output value.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"NALMEFENE","year":"2021","qtr":"Q1","strtotime":1616351400,"product":"NALMEFENE HYDROCHLORIDE - BULK DRUG *GST TAX INV.NO. 70000917 DT 18.03.2021 *LUT ARN NO.: AD2403210071130 DT: 08.03.2021","address":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,","city":"MUMBAI ,MAHARASHTRA","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"BRISTOL","customer":"BIO-TECHNE","customerCountry":"UNITED KINGDOM","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"146.9","totalValueFC":"1453.9","currency":"USD","unitRateINR":10584.4,"date":"22-Mar-2021","totalValueINR":"105844","totalValueInUsd":"1453.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"9543998","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624559400,"product":"NALMEFENE HYDROCHLORIDE (TAX INV NO. 700 00945 DT 24.06.2021)(LUT ARN :AD24032100 71130 DT:08.03.2021)","address":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,","city":"MUMBAI ,MAHARASHTRA","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"SHENZHEN","customer":"WUHAN YUNSUN PHARMACEUTICAL CO.,LTD","customerCountry":"CHINA","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"40.1","totalValueFC":"19634.7","currency":"USD","unitRateINR":2888.0934600000001,"date":"25-Jun-2021","totalValueINR":"1444046.73","totalValueInUsd":"19634.7","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"2677163","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657823400,"product":"NALMEFENE HYDROCHLORIDE","address":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI","city":"MUMBAI","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"XINYI, CHINA","customer":"SHAANXI DIDEU MEDICHEM ","customerCountry":"CHINA","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"50","totalValueFC":"2389.4","currency":"USD","unitRateINR":3800,"date":"15-Jul-2022","totalValueINR":"190000","totalValueInUsd":"2389.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"2830465","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716748200,"product":"NALMEFENE STANDARD (2GRAMS X 1VIAL)","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"LUPIN LTD","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"NOVEL LABORATORIES, INC.","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"5000","totalValueFC":"100.4","currency":"INR","unitRateINR":4182.7449999999999,"date":"27-May-2024","totalValueINR":"8365.49","totalValueInUsd":"100.4","indian_port":"Bombay Air","hs_no":"29391900","bill_no":"1189967","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"159, C.S.T. ROAD,, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667241000,"product":"NALMEFENE BASE (772) B12613P3 (100 MG)","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"CIPLA","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"45000","totalValueFC":"4627.5","currency":"USD","unitRateINR":"3776632.7","date":"01-Nov-2022","totalValueINR":"377663.27","totalValueInUsd":"4627.5","indian_port":"BOMBAY AIR","hs_no":"29391900","bill_no":"3112963","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667241000,"product":"NALMEFENE HCL ARS 0.0 MG CONTAINER (100 MG)","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"CIPLA","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"25000","totalValueFC":"2570.8","currency":"USD","unitRateINR":"2098129.3","date":"01-Nov-2022","totalValueINR":"209812.93","totalValueInUsd":"2570.8","indian_port":"BOMBAY AIR","hs_no":"29391900","bill_no":"3112963","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697653800,"product":"NALMEFENE HYDROCHLORIDE","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"CIPLA","customerCountry":"INDIA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"40000","totalValueFC":"8091.9","currency":"USD","unitRateINR":"3367423.8","date":"19-Oct-2023","totalValueINR":"673484.76","totalValueInUsd":"8091.9","indian_port":"Bombay Air","hs_no":"29391900","bill_no":"8376699","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"PERTH HOUSEMILLENNIUM WAY, DUNSTONCHESTERFILED, DERBYSHIRE S41 8ND UNITED KINGDOM","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702233000,"product":"(N.C.V) NALMEFENE HYDROCHLORIDE","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.001","unit":"KGS","unitRateFc":"40000","totalValueFC":"40.5","currency":"USD","unitRateINR":"3373720","date":"11-Dec-2023","totalValueINR":"3373.72","totalValueInUsd":"40.5","indian_port":"Bombay Air","hs_no":"29391900","bill_no":"9171755","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"PERTH HOUSE MILLENNIUM WAY, DUNSTONCHESTERFILED, DERBYSHIRE S41 8ND Chester, , United Kingdom United Kingdom","customerAddress":"159, C.S.T. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702233000,"product":"NALMEFENE HYDROCHLORIDE","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"0.45","actualQuantity":"0.45","unit":"KGS","unitRateFc":"40000","totalValueFC":"18237.8","currency":"USD","unitRateINR":"3373719.7","date":"11-Dec-2023","totalValueINR":"1518173.88","totalValueInUsd":"18237.8","indian_port":"Bombay Air","hs_no":"29391900","bill_no":"9171755","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"PERTH HOUSE MILLENNIUM WAY, DUNSTONCHESTERFILED, DERBYSHIRE S41 8ND Chester, , United Kingdom United Kingdom","customerAddress":"159, C.S.T. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702837800,"product":"NALMEFENE HYDROCHLORIDE","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO","customer":"CIPLA","customerCountry":"INDIA","quantity":"0.45","actualQuantity":"450","unit":"GMS","unitRateFc":"40","totalValueFC":"18236.2","currency":"USD","unitRateINR":"3373.4","date":"18-Dec-2023","totalValueINR":"1518037","totalValueInUsd":"18236.2","indian_port":"Indore-EPZ\/SEZ","hs_no":"29391900","bill_no":"1008195","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO","supplierAddress":"PERTH HOUSE MILLENNIUM WAY, DUNSTON CHESTERFIELD, DERBYSHIRE S41 8ND UK UNITED KINGDOM","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703010600,"product":"NALMEFENE HYDROCHLORIDE","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO","customer":"CIPLA","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"40000","totalValueFC":"40507.8","currency":"USD","unitRateINR":"3372000","date":"20-Dec-2023","totalValueINR":"3372000","totalValueInUsd":"40507.8","indian_port":"Indore-EPZ\/SEZ","hs_no":"29391900","bill_no":"1008291","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO","supplierAddress":"PERTH HOUSE MILLENNIUM WAY DUNSTON CHESTERFIELD DERBY SHIRE S41 8ND GB","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"NALMEFENE HYDROCHLORIDE","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"2.10","actualQuantity":"2.1","unit":"KGS","unitRateFc":"40000","totalValueFC":"84605","currency":"USD","unitRateINR":"3353709.5","date":"23-Dec-2023","totalValueINR":"7042789.99","totalValueInUsd":"84605","indian_port":"Bombay Air","hs_no":"29391900","bill_no":"9380245","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"PERTH HOUSE MILLENNIUM WAY, DUNSTONCHESTERFILED, DERBYSHIRE S41 8ND Chester, , United Kingdom United Kingdom","customerAddress":"159, C.S.T. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720636200,"product":"NALMEFENE HYDROCHLORIDE","address":"221, GOREGAON-MULUND LINK ROAD,","city":"BHANDUP WEST, MUMBAI","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"RUBICON RESEARCH","customerCountry":"INDIA","quantity":"0.24","actualQuantity":"0.24","unit":"KGS","unitRateFc":"55000","totalValueFC":"13485.7","currency":"USD","unitRateINR":"4697003.5","date":"11-Jul-2024","totalValueINR":"1127280.83","totalValueInUsd":"13485.7","indian_port":"Bombay Air","hs_no":"29391900","bill_no":"4451591","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"PERTH HOUSE, MILLENIUM WAYDUNSTON, CHESTERFIELDDERBYSHIRE, S41 8ND UNITED STATES US","customerAddress":"221, GOREGAON-MULUND LINK ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720636200,"product":"NALMEFENE HYDROCHLORIDE","address":"221, GOREGAON-MULUND LINK ROAD,","city":"BHANDUP WEST, MUMBAI","supplier":"MALLINCKRODT PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"RUBICON RESEARCH","customerCountry":"INDIA","quantity":"0.38","actualQuantity":"0.38","unit":"KGS","unitRateFc":"55000","totalValueFC":"21352.3","currency":"USD","unitRateINR":"4697003.4","date":"11-Jul-2024","totalValueINR":"1784861.31","totalValueInUsd":"21352.3","indian_port":"Bombay Air","hs_no":"29391900","bill_no":"4451591","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"PERTH HOUSE, MILLENIUM WAYDUNSTON, CHESTERFIELDDERBYSHIRE, S41 8ND UNITED STATES US","customerAddress":"221, GOREGAON-MULUND LINK ROAD,"}]
22-Mar-2021
11-Jul-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Zurnai

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 30, 2024

blank

01

Purdue Pharma

Canada
arrow
German Wound Congress
Not Confirmed

Purdue Pharma

Canada
arrow
German Wound Congress
Not Confirmed

Details : Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.

Product Name : Zurnai

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 30, 2024

blank

Details:

Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Nalmefene Hydrochloride-Generic

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 04, 2024

blank

02

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.

Product Name : Nalmefene Hydrochloride-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 04, 2024

blank

Details:

Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Zurnai

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 08, 2024

blank

03

Purdue Pharma

Canada
arrow
German Wound Congress
Not Confirmed

Purdue Pharma

Canada
arrow
German Wound Congress
Not Confirmed

Details : Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.

Product Name : Zurnai

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 08, 2024

blank

Details:

Zurnai (nalmefene hydrochloride) Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Zurnai

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 08, 2024

blank

04

Purdue Pharma

Canada
arrow
German Wound Congress
Not Confirmed

Purdue Pharma

Canada
arrow
German Wound Congress
Not Confirmed

Details : Zurnai (nalmefene hydrochloride) Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.

Product Name : Zurnai

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 08, 2024

blank
  • Deals

Details:

The grant will be used for the evaluation of nalmefene hydrochloride (HCl) injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Nalmefene Hydrochloride-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Purdue Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing March 27, 2024

blank

05

The University of New Mexico

Country
arrow
German Wound Congress
Not Confirmed

The University of New Mexico

Country
arrow
German Wound Congress
Not Confirmed

Details : The grant will be used for the evaluation of nalmefene hydrochloride (HCl) injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects.

Product Name : Nalmefene Hydrochloride-Generic

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 27, 2024

blank

Details:

The company intends to use the net proceeds for the advancement of its phase 2 trial evaluating, TH104 (nalmefene) for the treatment of moderate-to-severe cholestatic pruritis in primary biliary cholangitis.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TH104

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Thinkequity

Deal Size: $11.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering November 30, 2023

blank

06

Tharimmune

U.S.A
arrow
German Wound Congress
Not Confirmed

Tharimmune

U.S.A
arrow
German Wound Congress
Not Confirmed

Details : The company intends to use the net proceeds for the advancement of its phase 2 trial evaluating, TH104 (nalmefene) for the treatment of moderate-to-severe cholestatic pruritis in primary biliary cholangitis.

Product Name : TH104

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

November 30, 2023

blank

Details:

TH104 is a product which has been developed by embedding drug onto a proprietary transmucosal buccal film which adheres to the inside of the mouth. It isbeing evaluated for the treatment of chronic pruritis in primary biliary cholangitis (PBC).


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TH104

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 27, 2023

blank

07

Tharimmune

U.S.A
arrow
German Wound Congress
Not Confirmed

Tharimmune

U.S.A
arrow
German Wound Congress
Not Confirmed

Details : TH104 is a product which has been developed by embedding drug onto a proprietary transmucosal buccal film which adheres to the inside of the mouth. It isbeing evaluated for the treatment of chronic pruritis in primary biliary cholangitis (PBC).

Product Name : TH104

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 27, 2023

blank

Details:

Through the agreement, Hillstream aims to acquire a clinical stage asset, AV104 (nalmefene), an opioid antagonist, but first it intends to seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis with primary biliary cholangitis.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: AV104

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: Hillstream BioPharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 09, 2023

blank

08

Avior Bio

U.S.A
arrow
German Wound Congress
Not Confirmed

Avior Bio

U.S.A
arrow
German Wound Congress
Not Confirmed

Details : Through the agreement, Hillstream aims to acquire a clinical stage asset, AV104 (nalmefene), an opioid antagonist, but first it intends to seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis with primary biliar...

Product Name : AV104

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

November 09, 2023

blank

Details:

Opvee (nalmefene) nasal spray is an opioid receptor antagonist approved by the Food and Drug Administration (FDA) to for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: OPNT003

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 30, 2023

blank

09

Indivior

U.S.A
arrow
German Wound Congress
Not Confirmed

Indivior

U.S.A
arrow
German Wound Congress
Not Confirmed

Details : Opvee (nalmefene) nasal spray is an opioid receptor antagonist approved by the Food and Drug Administration (FDA) to for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patient...

Product Name : OPNT003

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 30, 2023

blank

Details:

Opvee (nalmefene) nasal spray is an opioid receptor antagonist approved by the Food and Drug Administration (FDA) to for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients.


Lead Product(s): Nalmefene Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: OPNT003

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 23, 2023

blank

10

Indivior

U.S.A
arrow
German Wound Congress
Not Confirmed

Indivior

U.S.A
arrow
German Wound Congress
Not Confirmed

Details : Opvee (nalmefene) nasal spray is an opioid receptor antagonist approved by the Food and Drug Administration (FDA) to for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patient...

Product Name : OPNT003

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 23, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

H. Lundbeck AS

Denmark
German Wound Congress
Not Confirmed
arrow

H. Lundbeck AS

Denmark
arrow
German Wound Congress
Not Confirmed

nalmefenhydrokloriddihydrat

Brand Name : Selincro

Dosage Form : FILM COATED PILL

Dosage Strength : 18 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

02

H. Lundbeck AS

Denmark
German Wound Congress
Not Confirmed
arrow

H. Lundbeck AS

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefene

Brand Name : Selincro

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

H. Lundbeck AS

Denmark
German Wound Congress
Not Confirmed
arrow

H. Lundbeck AS

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefene

Brand Name : Selincro

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

H. Lundbeck AS

Denmark
German Wound Congress
Not Confirmed
arrow

H. Lundbeck AS

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefenum

Brand Name : Selincro

Dosage Form : Filmtabl

Dosage Strength : 18mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

05

H. Lundbeck AS

Denmark
German Wound Congress
Not Confirmed
arrow

H. Lundbeck AS

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefenum

Brand Name : Selincro

Dosage Form : Filmtabl

Dosage Strength : 18mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

Hikma Pharmaceuticals

United Kingdom
German Wound Congress
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : REVEX

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Packaging :

Approval Date : 1995-04-17

Application Number : 20459

Regulatory Info : DISCN

Registration Country : USA

blank

07

Hikma Pharmaceuticals

United Kingdom
German Wound Congress
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : REVEX

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 2MG BASE/2ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Packaging :

Approval Date : 1995-04-17

Application Number : 20459

Regulatory Info : DISCN

Registration Country : USA

blank

08

Indivior

U.S.A
German Wound Congress
Not Confirmed
arrow

Indivior

U.S.A
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : OPVEE

Dosage Form : SPRAY;NASAL

Dosage Strength : EQ 2.7MG BASE/SPRAY

Packaging :

Approval Date : 2023-05-22

Application Number : 217470

Regulatory Info : RX

Registration Country : USA

blank

09

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : NALMEFENE HYDROCHLORIDE

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)

Packaging :

Approval Date : 2023-11-15

Application Number : 216007

Regulatory Info : RX

Registration Country : USA

blank

10

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : NALMEFENE HYDROCHLORIDE

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

Packaging :

Approval Date : 2023-11-15

Application Number : 216007

Regulatory Info : RX

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

HIKMA

United Kingdom
German Wound Congress
Not Confirmed
arrow

HIKMA

United Kingdom
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : REVEX

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Approval Date : 1995-04-17

Application Number : 20459

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

02

HIKMA

United Kingdom
German Wound Congress
Not Confirmed
arrow

HIKMA

United Kingdom
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : REVEX

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 2MG BASE/2ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Approval Date : 1995-04-17

Application Number : 20459

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

03

INDIVIOR

U.S.A
German Wound Congress
Not Confirmed
arrow

INDIVIOR

U.S.A
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : OPVEE

Dosage Form : SPRAY;NASAL

Dosage Strength : EQ 2.7MG BASE/SPRAY

Approval Date : 2023-05-22

Application Number : 217470

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

04

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : NALMEFENE HYDROCHLORIDE

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

Approval Date : 2022-02-08

Application Number : 212955

RX/OTC/DISCN : RX

RLD : No

TE Code : AP

blank

05

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : ZURNAI (AUTOINJECTOR)

Dosage Form : SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Dosage Strength : EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)

Approval Date : 2024-08-07

Application Number : 218590

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

06

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : NALMEFENE HYDROCHLORIDE

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)

Approval Date : 2023-11-15

Application Number : 216007

RX/OTC/DISCN : RX

RLD : No

TE Code :

blank

07

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : NALMEFENE HYDROCHLORIDE

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

Approval Date : 2023-11-15

Application Number : 216007

RX/OTC/DISCN : RX

RLD : No

TE Code : AP

blank

08

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Brand Name : NALMEFENE HYDROCHLORIDE

Dosage Form : SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Dosage Strength : 2MG BASE/2ML (EQ 1MGBASE/ML)

Approval Date :

Application Number : 216007

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

nalmefenhydrokloriddihydrat

Brand Name : Selincro

Dosage Form : FILM COATED PILL

Dosage Strength : 18 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

02

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefene

Brand Name : Selincro

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefene

Brand Name : Selincro

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefene

Brand Name : Selincro

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefenum

Brand Name : Selincro

Dosage Form : Filmtabl

Dosage Strength : 18mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Nalmefenum

Brand Name : Selincro

Dosage Form : Filmtabl

Dosage Strength : 18mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions
Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   

Impressions: 7254

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

#PharmaFlow by PHARMACOMPASS
24 Oct 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20241028862040/en

BUSINESSWIRE
28 Oct 2024

https://www.fda.gov/news-events/press-announcements/fda-approves-first-nalmefene-hydrochloride-auto-injector-reverse-opioid-overdose

FDA
09 Aug 2024

https://www.businesswire.com/news/home/20240807347421/en

BUSINESSWIRE
07 Aug 2024

https://www.businesswire.com/news/home/20240408735407/en

BUSINESSWIRE
08 Apr 2024

https://www.businesswire.com/news/home/20240327450490/en

BUSINESSWIRE
27 Mar 2024

https://www.prnewswire.com/news-releases/indivior-announces-publication-demonstrating-that-opvee-nalmefene-nasal-spray-rapidly-reverses-effects-of-opioid-induced-respiratory-depression-in-head-to-head-study-against-intranasal-naloxone-302085667.html

PR NEWSWIRE
11 Mar 2024

Global Sales Information

Do you need Business Intel? Ask us

Regulatory FDF Prices

read-more
read-more

01

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Price Per Pack (Euro) : 34.661

Published in :

Country : Norway

RX/OTC/DISCN :

blank

02

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Price Per Pack (Euro) : 64.581

Published in :

Country : Norway

RX/OTC/DISCN :

blank

03

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 18 mg

Price Per Pack (Euro) : 124.42

Published in :

Country : Norway

RX/OTC/DISCN :

blank

04

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

Dosage Form : Filmtabl

Dosage Strength : 18mg

Price Per Pack (Euro) : 59.76

Published in :

Country : Switzerland

RX/OTC/DISCN : Class B

blank

05

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Brand Name : Selincro

Denmark
arrow
German Wound Congress
Not Confirmed

Nalmefene Hydrochloride

Dosage Form : Filmtabl

Dosage Strength : 18mg

Price Per Pack (Euro) : 165.85

Published in :

Country : Switzerland

RX/OTC/DISCN : Class B

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
German Wound Congress
Not Confirmed

INDIVIOR

U.S.A
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 11458091

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 217470

Patent Use Code : U-3630

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-07-10

blank

02

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 10881798

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-02-11

blank

03

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 9364610

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-21

blank

04

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 11446440

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-21

blank

05

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 9533102

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-01-24

blank

06

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 11857547

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-11-05

blank

07

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 8021335

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-10-04

blank

08

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 11446441

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-01-24

blank

09

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 11813435

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-02-25

blank

10

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

US Patent Number : 11185642

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 218590

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-28

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
German Wound Congress
Not Confirmed

INDIVIOR

U.S.A
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Exclusivity Code : NP

Exclusivity Expiration Date : 2026-05-22

Application Number : 217470

Product Number : 1

Exclusivity Details :

blank

02

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

NALMEFENE HYDROCHLORIDE

Exclusivity Code : NP

Exclusivity Expiration Date : 2027-08-07

Application Number : 218590

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

Others

read-more
read-more

01

German Wound Congress
Not Confirmed

02

German Wound Congress
Not Confirmed

03

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Nalmefene Base ARS

CAS Number :

Quantity Per Vial :

Sale Unit :

Price :

Details :

Monograph :

Storage :

Code/Batch No : 1608

blank

04

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Nalmefene HCl ARS

CAS Number :

Quantity Per Vial :

Sale Unit :

Price :

Details :

Monograph :

Storage :

Code/Batch No : 1909

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 58895-64-0 / Nalmefene Hydrochloride API manufacturers, exporters & distributors?

Nalmefene Hydrochloride manufacturers, exporters & distributors 1

31

PharmaCompass offers a list of Nalmefene Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nalmefene Hydrochloride manufacturer or Nalmefene Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nalmefene Hydrochloride manufacturer or Nalmefene Hydrochloride supplier.

PharmaCompass also assists you with knowing the Nalmefene Hydrochloride API Price utilized in the formulation of products. Nalmefene Hydrochloride API Price is not always fixed or binding as the Nalmefene Hydrochloride Price is obtained through a variety of data sources. The Nalmefene Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Nalmefene Hydrochloride

Synonyms

58895-64-0, Nalmefene hcl, Revex, Nalmefenehydrochloride, Jf-1 hydrochloride, K7k69qc05x

Cas Number

58895-64-0

Unique Ingredient Identifier (UNII)

K7K69QC05X

About Nalmefene Hydrochloride

Nalmefene Hydrochloride is the hydrochloride salt form of nalmefene, a naltrexone analogue with opioid antagonistic property. Nalmefene antagonizes the effects of opioids by competing for the opioid receptors in the CNS. This results in reversal of the effects of the opioids, including reversal of analgesia, euphoria, respiratory depression, hypotension, sedation and physical dependence.

Nalmefene Hydrochloride Manufacturers

A Nalmefene Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nalmefene Hydrochloride , including repackagers and relabelers. The FDA regulates Nalmefene Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nalmefene Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Nalmefene Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Nalmefene Hydrochloride Suppliers

A Nalmefene Hydrochloride supplier is an individual or a company that provides Nalmefene Hydrochloride active pharmaceutical ingredient (API) or Nalmefene Hydrochloride finished formulations upon request. The Nalmefene Hydrochloride suppliers may include Nalmefene Hydrochloride API manufacturers, exporters, distributors and traders.

click here to find a list of Nalmefene Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Nalmefene Hydrochloride USDMF

A Nalmefene Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Nalmefene Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Nalmefene Hydrochloride DMFs exist exist since differing nations have different regulations, such as Nalmefene Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Nalmefene Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Nalmefene Hydrochloride USDMF includes data on Nalmefene Hydrochloride 's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nalmefene Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Nalmefene Hydrochloride suppliers with USDMF on PharmaCompass.

Nalmefene Hydrochloride JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Nalmefene Hydrochloride Drug Master File in Japan (Nalmefene Hydrochloride JDMF) empowers Nalmefene Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Nalmefene Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Nalmefene Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Nalmefene Hydrochloride suppliers with JDMF on PharmaCompass.

Nalmefene Hydrochloride WC

A Nalmefene Hydrochloride written confirmation (Nalmefene Hydrochloride WC) is an official document issued by a regulatory agency to a Nalmefene Hydrochloride manufacturer, verifying that the manufacturing facility of a Nalmefene Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nalmefene Hydrochloride APIs or Nalmefene Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Nalmefene Hydrochloride WC (written confirmation) as part of the regulatory process.

click here to find a list of Nalmefene Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.

Nalmefene Hydrochloride NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nalmefene Hydrochloride as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Nalmefene Hydrochloride API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Nalmefene Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Nalmefene Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nalmefene Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Nalmefene Hydrochloride suppliers with NDC on PharmaCompass.

Nalmefene Hydrochloride GMP

Nalmefene Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Nalmefene Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nalmefene Hydrochloride GMP manufacturer or Nalmefene Hydrochloride GMP API supplier for your needs.

Nalmefene Hydrochloride CoA

A Nalmefene Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Nalmefene Hydrochloride 's compliance with Nalmefene Hydrochloride specifications and serves as a tool for batch-level quality control.

Nalmefene Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Nalmefene Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Nalmefene Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Nalmefene Hydrochloride EP), Nalmefene Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nalmefene Hydrochloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty